NextCure has partnered with Simcere to develop the ADC SIM0505, targeting CDH6 for solid tumors.
The deal includes an undisclosed upfront payment plus development, regulatory, and sales milestones up to $745 million.
NextCure will initiate a Phase I trial in the U.S. in the third quarter of 2025.
Simcere's proprietary payload is highlighted for its potential improved safety and efficacy profile.